Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Immune Checkpoint Inhibition

Novel Immunotherapeutic Approaches

Current Standard of Care Second-Line for Platinum-Refractory SCCHN

CheckMate 141 Study Design

CheckMate 141 1-Year OS

CheckMate 141 Treatment-Related Adverse Events

CheckMate-141 OS at 2-Year Follow-Up

OS Benefit in Patients With PD-L1+ Tumors 6-Month vs 2-Year Follow-Up

OS Benefit in Patients With PD-L1- Tumors 6-Month vs 2-Year Follow-Up

PD-L1 Status in Patient Selection

Platinum-Refractory Patients Locally Advanced vs Recurrent Metastatic Setting

Pembrolizumab Background

KEYNOTE-040 Study Design

KEYNOTE-040 Efficacy and Safety in the ITT Population

CheckMate-141 vs KEYNOTE-040

KEYNOTE-040 Update Efficacy in PD-L1 CPS ≥ 1 and TPS ≥ 50% Populations

Combination Immunotherapies Rationale

Combination Immunotherapies Second-Line for SCCHN

Combination Immunotherapies First-Line for SCCHN

Pseudoprogression and Hyperprogression

Treatment Beyond Progression Continued Immunotherapy vs Salvage Chemotherapy

Immune Checkpoint Inhibition Locally Advanced SCCHN

Caution in the Development of Novel Targets PD-1 Inhibitors Plus Epacadostat

Targets on the Horizon STAT3

Targets on the Horizon OX40

Practicalities of Use

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)